Drotaverine pills 40mg №28

Mechanism of action

Myotropic antispasmodic, isoquinoline derivative. The chemical structure and pharmacological properties similar to papaverine, but has a stronger and more lasting effect. Reduces the flow of Calcium ions in smooth muscle cells (inhibits phosphodiesterase, leads to the accumulation of intracellular cyclic adenosine monophosphate). Reduces the tone of smooth muscles of internal organs and intestinal motility, dilates blood vessels. Does not affect the autonomic nervous system, does not penetrate into the central nervous system.

The presence of a direct effect on smooth muscles can be used as an antispasmodic in cases where drugs from the m-holinoblokatori group are contraindicated (angle-closure glaucoma, prostatic hyperplasia).

Pharmacokinetics

Oral absorption is high, the period of semi-absorption is 12 minutes. Bioavailability - 100%. Evenly distributed in the tissues, penetrates into the smooth muscle cells. C_max in blood plasma - 2 hours. Communication with plasma proteins - 95-98%. Mainly excreted by the kidneys, to a lesser extent - with bile. Does not penetrate the blood-brain barrier.

Indications for use of the drug Drotaverine

Spasm of smooth muscles in diseases of the biliary tract: cholecystolithiasis, cholangiolithiasis, cholecystitis, pericholecystitis, cholangitis, inflammation of the duodenal papilla.

Spasm of smooth muscles in diseases of the urinary tract: nephrourolithiasis, uretrolithiasis, pyelitis, cystitis, spasm of the bladder. As an adjuvant therapy: with spasms of the smooth muscles of the gastrointestinal tract: gastric ulcer and 12 duodenal ulcer, gastritis, cardia and pylorus spasm, enteritis, colitis, spastic colitis with constipation and irritable bowel syndrome with flatulence; tensor headache; algomenorrhea, threatening miscarriage, threatening preterm delivery; spasm of the uterus pharynx during labor, prolonged opening of the pharynx, postpartum contractions.

When conducting some instrumental studies, incl. cholecystography.

Dosage and administration

, inside on 40-80 mg (1-2 tablets) 2-3 times a day.

, inside at the age of 3-6 years - 40-120 mg in 2-3 doses, the maximum daily dose is 120 mg; 6-18 years old - 80-200 mg in 2-5 doses, the maximum daily dose is 240 mg.

Side effect

Dizziness, headache, insomnia, palpitations, tachycardia, feeling hot, increased sweating, nausea, constipation, lowering blood pressure, allergic skin reactions, angioneurotic edema, urticaria, rash, itching.

Contraindications to the use of the drug Drotaverine

Hypersensitivity to the components of the drug, severe hepatic, renal failure, lactation period, children's age up to 3 years, galactose intolerance, lactase deficiency, glucose-galactose malabsorption.

Carefully. Severe atherosclerosis of the coronary arteries, prostatic hyperplasia, angle-closure glaucoma, gestation period.

The use of the drug Drotaverine during pregnancy and breastfeeding

Controlled studies in pregnant women have not been conducted, but the potential benefits may justify the use of drotaverine for the mother, despite the possible risk to the fetus. Contraindicated during breastfeeding.

Application for violations of the liver

Contraindicated in severe liver failure.

Application for violations of kidney function

Contraindicated in severe renal failure.

Use in children

Contraindicated in children under 3 years.

Special notes

During the period of treatment, it is necessary to refrain from driving vehicles and engaging in other potentially hazardous activities that require high concentration of attention and psychomotor speed.

Overdosage

Symptoms: exceeding the dose violates the atrio-ventricular conduction, reduces the excitability of the heart muscle, can cause cardiac arrest and depression of the respiratory center.

Treatment: the patient must be under the close supervision of a physician and receive symptomatic and supportive treatment. It is recommended to induce vomiting and / or flush the stomach.

Drug interaction

With simultaneous use drotaverin may weaken the anti-parkinsonian effect of levodopa.Enhances the action of papaverine, bendazole and other antispasmodics (including m-holinoblokatorov), lower blood pressure caused by tricyclic antidepressants, quinidine and procainamide.

Phenobarbital increases the severity of the antispasmodic action of drotaverine. Reduces spasmogenic activity of morphine.

Terms and conditions of storage

To store a preparation in the dry, protected from light place at a temperature not above 25 ° C. Keep out of the reach of children.